|
Apr 15
|
In the wake of Bristol-Myers Squibb Company's (NYSE:BMY) latest US$5.7b market cap drop, institutional owners may be forced to take severe actions
|
|
Jan 2
|
European Medicines Agency Validates Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
|
|
Dec 27
|
A Tale of Two Pharmas: Can Obesity Firms Continue Their Outperformance in 2024?
|
|
Dec 27
|
Trending tickers: Intel | Tencent | RayzeBio | Astrazeneca
|
|
Dec 26
|
Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers
|
|
Dec 26
|
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
|
|
Dec 22
|
Rocket Lab, Coinbase, Bristol Myers-Karuna deal: Trending tickers
|
|
Dec 22
|
Bristol Myers acquiring Karuna Therapeutics in $14B deal
|
|
Dec 22
|
Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
|
|
Dec 22
|
Bristol Myers Squibb to Present at J.P. Morgan’s 42nd Annual Healthcare Conference
|
|
Dec 22
|
Bristol Myers to Buy Karuna Therapeutics for $14 Billion
|
|
Dec 20
|
Bristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
|
|
Dec 15
|
Bristol Myers Squibb to Discontinue Metastatic Colorectal Cancer Trial
|
|
Dec 15
|
Bristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
|
|
Dec 15
|
Bristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
|
|
Dec 14
|
Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
|
|
Dec 12
|
Two Early Studies Evaluating Potential First-in-Class CELMoD™ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
|
|
Dec 12
|
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
|
|
Dec 12
|
Abecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
|
|
Dec 11
|
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
|